[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance PCat. No. 1946 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
Biological Activity
Broad spectrum neuropeptide antagonist/inverse agonist. Potent full inverse agonist for the ghrelin receptor (EC50 = 5.2 nM); diminishes constitutive ghrelin receptor signaling. Also antagonist at tachykinin, bradykinin, CCK and bombesin receptors. Induces apoptosis and inhibits cancer cell growth in vitro.Technical Data
M.Wt:(Modifications: Arg-1 = D-Arg, Phe-5 = D-Phe, Trp-7 = Trp-9 = D-Trp, Leu-11 = C-terminal amide)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
References
Reeve and Bleehen (1994) [D-Arg1, D-Phe5, D-Trp7,9, Leu11] Substance P induces apoptosis in lung cancer cells in vitro. Biochem.Biophys.Res.Commun. 199 1313. PMID: 7511895.
Jarpe et al (1998) [D-Arg1, D-Phe5, D-Trp7,9, Leu11] Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J.Biol.Chem. 273 3097. PMID: 9446627.
Holst et al (2003) High constitutive signaling of the ghrelin receptor - identification of a potent inverse agonist. Mol.Endocrinol. 17 2201. PMID: 12907757.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, supplier, Substance, P, broad, spectrum, neuropeptide, receptor, antagonists, inverse, agonists, Potent, ghrelin, Tachykinin, Neurokinin, Receptors, GHS-R1a, Growth, Hormone, Secretagog, Receptor, 1a, Ghrelin, [D-Arg1D-Phe5D-Trp79Leu11]-SubstanceP, neuropeptides
Quick Order
Find multiple products by catalog number
New Products in this Area
Oxytocin analog
ML 221Apelin receptor (APJ) antagonist
Q94 hydrochlorideNegative allosteric modulator at PAR1 receptor
FSLLRY-NH2PAR2 peptide antagonist
SB 611812Urotensin-II (UT) antagonist; attenuates cardiac dysfunction
TC-MCH 7cSelective melanin-concentrating hormone receptor 1 (MCH1R) antagonist
CYM 9484Potent NPY Y2 receptor antagonist
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.





